Chemobrain: uma revisão de escopo de ensaios randomizados
DOI:
https://doi.org/10.34024/rnc.2024.v32.16574Palavras-chave:
comprometimento cognitivo relacionado à quimioterapia, neoplasias, cogniçãoResumo
Introdução. O comprometimento cognitivo relacionado à quimioterapia tem sido referido como um efeito colateral à terapia anticâncer de longo prazo e impacto. Objetivo. Descrever as evidências dos ensaios clínicos randomizados sobre o comprometimento cognitivo relacionado à quimioterapia. Método. Esta revisão de escopo utilizou as bases de dados Web of Science, ScienceDirect, PubMed, SciELO, PsycNet, Biblioteca Virtual em Saúde e LILACS usando os descritores “chemobrain” e “chemotherapy-induced cognitive impairment”. Apenas a ScienceDirect e PubMed geraram artigos elegíveis à pesquisa, um montante de 15.035 estudos, ficando 12 elegíveis para inclusão e análise. Resultados. Os estudos são compostos majoritariamente por pacientes com câncer de mama, numa média de idade de 43 e 56 anos, nível educacional de médio a alto, com maior frequência de estadiamento nível II, submetidas à quimioterapia e com presença de comprometimento cognitivo percebido e/ou testado por baterias neuropsicológicas. As intervenções são voltadas a medicina complementar e integrativa, psicoterapias, treinamento cognitivo, estratégias compensatórias com intervenções de treinamento cognitivo e intervenções farmacológicas. Conclusão. Os estudos apontam os efeitos da intervenção na mediação de marcadores inflamatórios, alterações no volume e conectividade cerebral e nos fatores psicossociais, apresentam um modelo multifatorial do comprometimento cognitivo relacionado à quimioterapia. Este estudo pode delimitar caminhos para a decisão clínica, meios de avaliação e cuidado à pacientes oncológicos.
Métricas
Referências
Mendonça e Silva DR, Curado MP, Fregnani JHTG (org). Observatório do câncer: Registro Hospitalar de Câncer do A.C. Camargo Cancer Center 2000 a 2020. São Paulo: Fundação Antônio Prudente; 2023; 43p. https://accamargo.org.br/sites/default/files/2023/04/observatorio_do_cancer_rhc_2000-2020.pdf
Almeida VL, Leitão A, Reina LCB, Montanari CA, Donnici CL, Lopes MTP. Câncer e agentes antineoplásicos ciclo-celular específicos e ciclo-celular não específicos que interagem com o DNA: uma introdução. Quím Nova 2005;28:118-29. https://doi.org/10.1590/S0100-40422005000100021
Monteiro APVB, Fortes RC. Principais reações adversas provocadas pelos quimioterápicos: Contribuição da enfermagem frente às reações adversas e/ou efeitos colaterais relacionados à quimioterapia. Braz J Develop 2022;8:6790-806. https://doi.org/10.34117/bjdv8n1-458
Salvetti MG, Machado CSP, Donato SCT, Silva AM. Prevalência de sintomas e qualidade de vida de pacientes com câncer. Rev Bras Enferm 2020;73:7. https://doi.org/10.1590/0034-7167-2018-0287
Rao V, Bhushan R, Kumari P, Cheruku SP, Ravichandiran V, Kumar N. Chapter Two- Chemobrain: A review on mechanistic insight, targets and treatments. Adv Cancer Res 2022; pp.29-76. https://doi.org/10.1016/bs.acr.2022.04.001
Janelsins MC, Heckler CE, Peppone LJ, Ahles TA, Mohile SG, Mustian KM, et al. Longitudinal Trajectory and Characterization of Cancer-Related Cognitive Impairment in a Nationwide Cohort Study. J Clin Oncol 2018;36:3231-9. https://doi.org/10.1200/JCO.2018.78.6624
Janelsins MC, Kohli S, Mohile SG, Usuki K, Ahles TA, Morrow GR. An update on cancer- and chemotherapy-related cognitive dysfunction: current status. Semin Oncol 2011;38:431-8. https://doi.org/10.1053/j.seminoncol.2011.03.014
Wefel JS, Kesler SR, Noll KR, Schagen SB. Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA Cancer J Clin 2015;65:123-38. https://doi.org/10.3322/caac.21258
Liu S, Ni J, Yan F, Yin N, Li X, Ma R, et al. Functional changes of the prefrontal cortex, insula, caudate and associated cognitive impairment (chemobrain) in NSCLC patients receiving different chemotherapy regimen. Front Oncol 2022;12:1027515. https://doi.org/10.3389/fonc.2022.1027515
Tang M, Zhao S, Liu JX, Liu X, Guo YX, Wang GY, et al. Paclitaxel induces cognitive impairment via necroptosis, decreased synaptic plasticity and M1 polarisation of microglia. Pharm Biol 2022;60:1556-65. https://doi.org/10.1080/13880209.2022.2108064
Was H, Borkowska A, Bagues A, Tu L, Liu JYH, Lu Z, et al. Mechanisms of Chemotherapy-Induced Neurotoxicity. Front Pharmacol 2022;13:750507. https://doi.org/10.3389/fphar.2022.750507
Vance DE, Frank JSP, Bail J, Triebel KL, Niccolai LM, Gerstenecker A, et al. Intervenções para déficits cognitivos em sobreviventes de câncer de mama tratados com quimioterapia. Enferm Câncer 2017;40:11-27. https://doi.org/10.1097/NCC.0000000000000349
Elagami RA, Gallegos CL, Laux CM, Tedesco TK, Raggio DP. A Importância dos estudos clínicos randomizados e seu impacto na tomada de decisão clínica. Rev Cient CRO-RJ 2022;7:3-8. https://doi.org/10.29327/244963.7.1-2
Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med 2018;169:467-73. https://doi.org/10.7326/M18-0850
Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Syst Rev 2016;210:10. https://doi.org/10.1186/s13643-016-0384-4
Tack L, Lefebvre T, Lycke M, Langenaeken C, Fontaine C, Borms M, et al. A randomised wait-list controlled trial to evaluate Emotional Freedom Techniques for self-reported cancer-related cognitive impairment in cancer survivors (EMOTICON). E Clin Med 2021;39:101081. https://doi.org/10.1016/j.eclinm.2021.101081
Bellens A, Roelant E, Sabbe B, Peeters M, van Dam PA. A video-game based cognitive training for breast cancer survivors with cognitive impairment: A prospective randomized pilot trial. Breast 2020;53:23-32. https://doi.org/10.1016/j.breast.2020.06.003
Santos M, Hardy-Léger I, Rigal O, Licaj I, Dauchy S, Levy C, et al. Cognitive rehabilitation program to improve cognition of cancer patients treated with chemotherapy: A 3-arm randomized trial. Cancer 2020;126:5328-36. https://doi.org/10.1002/cncr.33186
Koevoets EW, Schagen SB, Ruiter MB, Geerlings MI, Witlox L, van der Wall E, et al. PAM study group. Effect of physical exercise on cognitive function after chemotherapy in patients with breast cancer: a randomized controlled trial (PAM study). Breast Cancer Res 2022;24:36. https://doi.org/10.1186/s13058-022-01530-2
Koevoets EW, Geerlings MI, Monninkhof EM, Mandl R, Witlox L, van der Wall E, et al. PAM study group. Effect of physical exercise on the hippocampus and global grey matter volume in breast cancer patients: A randomized controlled trial (PAM study). Neuroimage Clin 2023;37:103292. https://doi.org/10.1016/j.nicl.2022.103292
Van der Gucht K, Ahmadoun S, Melis M, de Cloe E, Sleurs C, Radwan A, et al. Effects of a mindfulness-based intervention on cancer-related cognitive impairment: Results of a randomized controlled functional magnetic resonance imaging pilot study. Cancer 2020;126:4246-55. https://doi.org/10.1002/cncr.33074
Henneghan AM, Fico BG, Wright ML, Kesler SR, Harrison ML. Effects of meditation compared to music listening on biomarkers in breast cancer survivors with cognitive complaints: secondary outcomes of a pilot randomized control trial. Explore (NY) 2022;18:657-62. https://doi.org/10.1016/j.explore.2021.10.011
Ding K, Zhang X, Zhao J, Zuo H, Bi Z, Cheng H. Managing Cancer and Living Meaningfully (CALM) Intervention on Chemotherapy-Related Cognitive Impairment in Breast Cancer Survivors. Integr Cancer Ther 2020;19:1534735420938450. https://doi.org/10.1177/1534735420938450
Vega JN, Albert KM, Mayer IA, Taylor WD, Newhouse PA. Nicotinic treatment of post-chemotherapy subjective cognitive impairment: a pilot study. J Cancer Surviv 2019;13:673-86. https://doi.org/10.1007/s11764-019-00786-6
Vega JN, Albert KM, Mayer IA, Taylor WD, Newhouse PA. Subjective cognition and mood in persistent chemotherapy-related cognitive impairment. J Cancer Surviv 2022;16:614-23. https://doi.org/10.1007/s11764-021-01055-1
Jacobs W, Schagen SB, Brouwer SM, Kieffer JM, Baas IO, Los M, et al. The Effects of Being Informed About Chemotherapy-Related Cognitive Symptoms With And Without Self-Affirmation on Perceived Cognitive Symptoms of Breast Cancer Patients: A Randomized Prospective, Longitudinal Study. Clin Breast Cancer 2022;22:439-54. https://doi.org/10.1016/j.clbc.2022.03.001
Yao S, Ding K, Liu S, Zhang Q, Li W, Tang L, et al. The Managing Cancer and Living Meaningfully (CALM) Intervention Alleviates Chemotherapy-Related Cognitive Impairment in Patients with Breast Cancer by Modulating Pan-Immune-Inflammation Values. Integr Cancer Ther 2022;21:15347354221140498. https://doi.org/10.1177/15347354221140498
Lima-Costa AR, Bonfá-Araujo B. Construindo escalas de autorrelato: O que fazer? Aval Psicol 2022;21:329-38. https://doi.org/10.15689/ap.2022.2103.21860.09
Hurria A, Somlo G, Ahles T. Renomeando “Chemobrain”. Invest Câncer 2007;25:373-7. https://doi.org/10.1080/07357900701506672
Franzoi MA, Rosa DD, Zaffaroni F, Werutsky G, Simon S, Bines J, et al. Advanced Stage at Diagnosis and Worse Clinicopathologic Features in Young Women with Breast Cancer in Brazil: A Subanalysis of the AMAZONA III Study (GBECAM 0115). J Glob Oncol 2019;5:1-10. https://doi.org/10.1200/JGO.19.00263
Sharma N, Srivastav AK, Samuel AJ. Ensaio clínico randomizado: padrão ouro de desenhos experimentais - importância, vantagens, desvantagens e preconceitos. Rev Pesq Fisio 2020;10:512-9. https://doi.org/10.17267/2238-2704rpf.v10i3.3039
Bray VJ, Dhillon HM, Vardy JL. Revisão sistemática da função cognitiva autorreferida em pacientes com câncer após tratamento quimioterápico. J Sobreviv Câncer 2018;12:537-59. https://doi.org/10.1007/s11764-018-0692-x
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2024 Anna Carolina da Silva Monteiro, Dalciney Máximo Diniz, Talita Francine Moraes de Gouveia, Elayne Costa da Silva
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Como Citar
Aprovado 2024-10-08
Publicado 2024-10-24
